Will Axitinib be included in the 2025 medical insurance catalog and its reimbursement ratio?

Axitinib is an oral small molecule tyrosine kinase inhibitor mainly used for the treatment of advanced renal cell carcinoma. With the continuous promotion of clinical application of targeted therapy drugs in China, axitinib has been officially launched in China and has been included in the medical insurance catalog. This means that patients can reduce their financial burden through medical insurance reimbursement when receiving treatment, thus improving drug accessibility and treatment compliance.

In terms of price, axitinib currently sold in the domestic market is mainly imported original drug, and the price of a single box is about more than 4,000 yuan. Although the overall cost is still high, the actual payment ratio of patients will be significantly reduced after being included in medical insurance. The specific medical insurance reimbursement ratio varies from region to region, and is generally around 50%—70% . Some regions may have further preferential reimbursement policies for patients with major diseases. Patients can consult the local medical insurance department or hospital pharmacy.

In addition to domestic original drugs, there are also relatively low-priced generic drugs on the overseas market, such as the Indian and Lao versions of axitinib. These generic drugs are basically the same as the original drugs in terms of drug ingredients and therapeutic effects, but the price is only a few hundred yuan per box, making them an alternative choice for some patients under financial pressure. However, it should be noted that when purchasing drugs through overseas channels, you need to pay attention to the safety and legality of formal channels to avoid buying fake drugs or substandard products.

Overall, the inclusion of axitinib in the medical insurance catalog has undoubtedly brought significant benefits to domestic kidney cancer patients, which not only ensures the accessibility of the drug, but also reduces the economic burden. For patients, they can choose the appropriate drug purchase channel according to their own economic conditions and medical insurance policies, so as to ensure the treatment effect and reduce the cost of medication. Rational use of drugs under the guidance of a doctor can maximize the clinical value of axitinib in the treatment of renal cell carcinoma.

Reference materials:https://www.drugs.com/